SCHEMBL6979084

SCHEMBL6979084

CC(C)[C@H](NS(=O)(=O)c1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.73
SLC1A2 P43004 1/20 0.73
SLC1A1 P43005 1/20 0.73
MMP13 P45452 9/20 0.68
ADAMTS4 O75173 7/20 0.68
MMP9 P14780 6/20 0.68
MMP2 P08253 5/20 0.68
MMP3 P08254 4/20 0.68
MMP1 P03956 3/20 0.68
MMP7 P09237 3/20 0.68
MMP12 P39900 4/20 0.62
NPSR1 Q6W5P4 1/20 0.59
MMP8 P22894 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8529829 1.00 SLC1A3 (0.73) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4
SCHEMBL10052446 0.89 MMP2 (0.78) MMP13ADAMTS4MMP9MMP2MMP3
SCHEMBL3233597 0.87 ADAMTS4 (0.68) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4
SCHEMBL7405654 0.87 SLC1A3 (0.60) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4
SCHEMBL8742293 0.87 SLC1A3 (0.67) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4
SCHEMBL1770811 0.86 MMP1 (0.67) SLC1A3SLC1A2SLC1A1MMP13MMP9
SCHEMBL12649188 0.86 MMP1 (0.67) SLC1A3SLC1A2SLC1A1MMP13MMP9
SCHEMBL10021355 0.86 MMP9 (0.70) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4
SCHEMBL10830548 0.85 ADAMTS4 (0.66) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4
SCHEMBL7322447 0.85 ADAMTS4 (0.66) SLC1A3SLC1A2SLC1A1MMP13ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0928786-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed
US-5614522-A SULFONAMIDE AND UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS G.D. SEARLE & CO. (US) 1997-03-25 US disclosed
EP-0558673-B1 RETROVIRAL PROTEASE INHIBITORS MONSANTO CO (US) 1996-04-17 EP disclosed
EP-0558673-A1 RETROVIRAL PROTEASE INHIBITORS. MONSANTO CO (US) 1993-09-08 EP disclosed
WO-1992008699-A1 RETROVIRAL PROTEASE INHIBITORS MONSANTO COMPANY (US) 1992-05-29 WO disclosed
EP-0236164-B1 DERIVATIVES OF N-ALPHA-ARYLSOLFONYLAMINOACYL P-AMIDINO-PHENYLALANINAMIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THEIR INTERMEDIATES SANOFI (FR) 1990-09-12 EP disclosed
EP-0236164-A1 Derivatives of N-alpha-arylsolfonylaminoacyl p-amidino-phenylalaninamides, process for their preparation, their use as medicaments and their intermediates SANOFI (FR) 1987-09-09 EP disclosed